TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals is a clinical stage pharmaceutical company committed to extending a healthy lifespan.

Founded 2014

Baltimore, United States 10 employees Post-IPO Equity Total: $22.00M Biotechnology, Pharmaceutical

MyMD Pharmaceuticals, with the slogan "Novel immunotherapies targeting autoimmune and age-related diseases", is a clinical stage biotech pharmaceutical company aiming to extend healthy lifespan through the development of two therapeutic platforms.

MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (TNF-α) and other pro-inflammatory cytokines. It is intended for the treatment of autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, as well as aging and longevity.

Additionally, MyMD is working on Supera-CBD, a drug platform based on a novel synthetic derivative of cannabidiol (CBD) targeting key receptors including CB2 and opioid receptors. This platform aims to address the ever-growing CBD market, which encompasses FDA approved drugs and non-regulated CBD products.

Founded in 2014 and headquartered in the United States, MyMD has recently secured a $7.00M post-IPO equity investment on 21 May 2024 from PharmaCyte Biotech. The company's focus on innovative solutions for debilitating diseases and aging-related issues makes it an intriguing venture for potential investors.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$7.00M	1	PharmaCyte Biotech	21 May 2024
Post IPO Equity	$15.00M	-		21 Feb 2023

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$7.00M

PharmaCyte Biotech

21 May 2024

Post IPO Equity

$15.00M

21 Feb 2023

FAQ About TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals is a clinical stage pharmaceutical company committed to extending a healthy lifespan.

TNF Pharmaceuticals, Inc. was founded in 2014.

TNF Pharmaceuticals, Inc. is headquartered in Baltimore, United States.

TNF Pharmaceuticals, Inc. operates in Biotechnology and Pharmaceutical. Its work centres on Immunotherapy, Autoimmune diseases, Aging and Longevity.

TNF Pharmaceuticals, Inc. has approximately 10 employees.

TNF Pharmaceuticals, Inc. has completed 2 funding rounds, raising a total of $22.00M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to TNF Pharmaceuticals, Inc. include InMed Pharmaceuticals, Corbus Pharmaceuticals, Inspirna, Inc., Synta Pharmaceuticals, Longboard Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

TNF Pharmaceuticals, Inc. and InMed Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

TNF Pharmaceuticals, Inc.

General Information

Discover More

About TNF Pharmaceuticals, Inc.

Funding Rounds & Investors (2)

TNF Pharmaceuticals, Inc. Alternatives & Competitors

FAQ About TNF Pharmaceuticals, Inc.